Drug Profile
Calcitonin - PPL Therapeutics
Alternative Names: Salcatonin - PPL TherapeuticsLatest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator PPL Therapeutics PLC
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 23 Jan 2017 Discontinued - Preclinical for Postmenopausal osteoporosis in United Kingdom (Parenteral)
- 09 Feb 2000 Suspended-Preclinical for Postmenopausal osteoporosis in United Kingdom (Unknown route)
- 12 Nov 1998 New profile